Montpellier, November 21, 2022 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active ingredients in nano micelles by the oral route, Aonys, announces the creation of a Scientific Advisory Board Permanent in order to support the Company in its research programs and clinical programs dedicated to neurodegenerative diseases.
The mission of the Permanent Scientific Advisory Board is to support the Management Board of Medesis Pharma by providing it with advice and expertise on its research and development strategy, more specifically in the knowledge of Alzheimer’s and Huntington’s diseases. New data generated, development programs and study plans will be discussed within this group to guide Medesis Pharma’s strategy in the development of Nanolithium. This advice will contribute to the academic and scientific quality of Medesis Pharma’s development programs for the treatment of neurodegenerative diseases, in particular Alzheimer’s disease, currently affecting more than 55 million people worldwide.[1]